CELCUITY INC

Insider buys of Celcuity stock signal confidence in its gene‑editing therapy and positive upside despite negative earnings.

Celcuity’s FDA‑approved Revtorpyk shows strong 35% response rates in PIK3CA‑mutant cancers, while insider sales by Baker Bros. reflect strategic liquidity moves, not a bearish signal.

Murphy Polly A’s 1,530‑unit RSU purchase signals strong insider confidence in Celcuity’s 2027 regulatory milestones, hinting at potential upside despite short‑term dilution.

Celcuity’s insider purchase and Phase 3 VIKTORIA‑1 results reveal growing confidence in its PI3K/mTOR drug gedatolisib, highlighting a pipeline‑centric strategy, partnership prospects, and market‑access challenges that investors should closely monit…

Celcuity insider sales under Rule 144 reveal a long‑term wealth‑management plan, not a sign of weakness. The company’s bispecific antibody pipeline, strong financial runway, and strategic partnerships still point to upside for shareholders and patie…

Celcuity insider buys 215 shares on vesting schedule – a bullish sign for the biotech’s solid‑tumor pipeline and future stock upside.

Celcuity Inc. insider sales, pipeline prospects, and valuation gaps—discover how the biotech’s strategy could unlock value or trigger risk.

Celcuity’s 892% 2025 rally and insider sale show strategic rebalancing, not panic—learn how its tech‑driven oncology pipeline and value‑based reimbursement strategy shape long‑term investor confidence.